Plant Name: Hedysarum polybotrys
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TDP1; HSD17B1; AKR1B1; UBE2N; TNKS; TNKS2; POLB; | |
| CA12; CA7; CA4; | |
| ESR1; ESR2; | |
| KDM4E; | |
| HIF1A; TP53; | |
| HTT; LMNA; NPC1; RAB9A; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | UBE2N | Ubiquitin-conjugating enzyme E2 N | P61088 | CHEMBL6089 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.513E-11 | 2.736E-07 | CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.860E-11 | 2.802E-07 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.960E-10 | 3.467E-06 | CYP19A1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.554E-08 | 4.230E-05 | CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.244E-08 | 5.313E-05 | CYP19A1, CYP1B1, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.902E-08 | 9.886E-05 | CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 9.504E-08 | 1.478E-04 | CYP3A4, ESR1, ESR2, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.582E-07 | 3.361E-04 | CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 3.906E-07 | 4.476E-04 | CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 4.544E-07 | 4.676E-04 | CA7, HIF1A, HTT, NPC1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.725E-07 | 4.676E-04 | CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.725E-07 | 4.676E-04 | CYP2C9, CYP2D6, CYP3A4 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 5.268E-07 | 4.987E-04 | AKR1B1, CA4, CYP19A1, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, ESR1, ESR2, HIF1A, HTT, KDM4E, LMNA, MAPT, NPC1, POLB, RAB9A, TDP1, TNKS, TNKS2, TP53, UBE2N |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.745E-07 | 7.579E-04 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.723E-06 | 1.150E-03 | ESR1, HIF1A, POLB, TNKS, TNKS2, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 1.742E-06 | 1.150E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.833E-06 | 1.667E-03 | CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 5.222E-06 | 2.774E-03 | CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 6.936E-06 | 3.596E-03 | CYP19A1, CYP3A4, ESR1 |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.044E-05 | 4.638E-03 | TNKS, TNKS2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.044E-05 | 4.638E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.044E-05 | 4.638E-03 | CYP2C9, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0010821; regulation of mitochondrion organization | 1.129E-05 | 4.821E-03 | HIF1A, HTT, LMNA, MAPT, TP53 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 1.496E-05 | 5.942E-03 | AKR1B1, CYP19A1, CYP1B1, CYP3A4, HIF1A, NPC1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.501E-05 | 5.942E-03 | CA12, CA4, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.764E-05 | 9.708E-03 | CA12, CA4, CA7 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 9.075E-07 | 3.963E-05 | HSD17B1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.831E-06 | 3.963E-05 | CYP2C9; CYP2D6; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.298E-06 | 3.963E-05 | CYP2C9; CYP2D6; CYP1B1; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.663E-06 | 5.055E-05 | CYP2C9; CYP1B1; CYP3A4; CYP2C19 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.310E-06 | 3.963E-05 | CA12; CA4; CA7 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.671E-05 | 3.618E-04 | HSD17B1; CYP1B1; CYP19A1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.968E-06 | 8.014E-05 | CYP2C9; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.046E-04 | 3.490E-03 | CYP2C9; CYP2D6; CYP2C19 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.714E-04 | 3.614E-03 | TP53; ESR1; HIF1A |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.255E-03 | 1.556E-02 | TP53; HIF1A; ESR1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.929E-03 | 1.811E-02 | CYP2C9; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.398E-03 | 2.023E-02 | CYP2C9; HSD17B1; AKR1B1; CYP2C19; CYP3A4; CYP19A1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.928E-03 | 1.936E-02 | ESR1; ESR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.411E-03 | 1.811E-02 | TP53; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.214E-03 | 1.811E-02 | CYP2C9; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 7.296E-03 | 3.146E-02 | ESR1; ESR2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; ESR1; ESR1 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; ESR1; ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |